Targeting Interleukin-31 in Prurigo

被引:0
|
作者
Metz, Martin [1 ,2 ]
机构
[1] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany
[2] Fraunhofer Inst Translat Med & Pharmacol ITMP, Immunol & Allergol, Berlin, Germany
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2023年 / 389卷 / 17期
关键词
D O I
10.1056/NEJMe2307584
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic prurigo is a debilitating, difficult-to-treat, and long-neglected disease characterized by chronic pruritus, signs of repeated scratching, and the presence of pruriginous lesions that may manifest as nodules, papules, plaques, umbilicated lesions, or all of these.1 The most commonly observed lesions are nodules, and if these are present, the disease is also called prurigo nodularis. Histologic findings of prurigo are epidermal hyperplasia, dermal fibrosis, and an inflammatory infiltrate. Itch is the dominant symptom and the most important driver of the severe impairment of quality of life, whereas the dermal changes are thought to contribute to the persistence of the disease. . . .
引用
收藏
页码:1619 / 1620
页数:2
相关论文
共 50 条
  • [1] A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis
    Mohammad Ali Nilforoushzadeh
    Nazila Heidari
    Yekta Ghane
    Amirhossein Heidari
    Arman Hajikarim-Hamedani
    SeyedAyin Hosseini
    Fariba Jaffary
    Minou Najar Nobari
    Pegah Tavakolzadeh
    Niloufar Najar Nobari
    Inflammopharmacology, 2024, 32 : 991 - 1003
  • [2] A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis
    Nilforoushzadeh, Mohammad Ali
    Heidari, Nazila
    Ghane, Yekta
    Heidari, Amirhossein
    Hajikarim-Hamedani, Arman
    Hosseini, Seyedayin
    Jaffary, Fariba
    Nobari, Minou Najar
    Tavakolzadeh, Pegah
    Nobari, Niloufar Najar
    INFLAMMOPHARMACOLOGY, 2024, 32 (02) : 991 - 1003
  • [3] Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis
    Furue, M.
    Yamamura, K.
    Kido-Nakahara, M.
    Nakahara, T.
    Fukui, Y.
    ALLERGY, 2018, 73 (01) : 29 - 36
  • [4] Is targeting interleukin-31 a cure for the itch? Lessons from amyloidosis
    Schreml, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (06) : 1192 - 1193
  • [5] Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis
    Nakashima, Chisa
    Otsuka, Atsushi
    Kabashima, Kenji
    EXPERIMENTAL DERMATOLOGY, 2018, 27 (04) : 327 - 331
  • [6] Interleukin-31 and Pruritic Skin
    Furue, Masutaka
    Furue, Mihoko
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (09)
  • [7] The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus
    Huang, Hua-Tuo
    Chen, Jian-Ming
    Guo, Jing
    Lan, Yan
    Wei, Ye-Sheng
    RHEUMATOLOGY INTERNATIONAL, 2016, 36 (06) : 799 - 805
  • [8] The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus
    Hua-Tuo Huang
    Jian-Ming Chen
    Jing Guo
    Yan Lan
    Ye-Sheng Wei
    Rheumatology International, 2016, 36 : 799 - 805
  • [9] Definition and Characterization of an Inhibitor for Interleukin-31
    Venereau, Emilie
    Diveu, Caroline
    Grimaud, Linda
    Ravon, Elisa
    Froger, Josy
    Preisser, Laurence
    Danger, Yannic
    Maillasson, Mike
    Garrigue-Antar, Laure
    Jacques, Yannick
    Chevalier, Sylvie
    Gascan, Hugues
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (20) : 14955 - 14963
  • [10] Interleukin-31: The "itchy" cytokine in inflammation and therapy
    Datsi, Angeliki
    Steinhoff, Martin
    Ahmad, Fareed
    Alam, Majid
    Buddenkotte, Joerg
    ALLERGY, 2021, 76 (10) : 2982 - 2997